Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection

Pathogens and Disease

Volumn 74, Issue 7, 2016, Pages

  Yang, Zhiyong ^a,b   Shi, Lianfa ^a   Yu, Hua ^a   Zhang, Yongrong ^a   Chen, Kevin ^a   Fleur, Ashley Saint ^a   Bai, Guang ^a   Feng, Hanping ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b FZata   (United States)

Author keywords

Adenovirus; Antibody; Clostridium difficile; Immunotherapy; Toxins; VHH

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL TOXIN; NANOBODY; NEUTRALIZING ANTIBODY; TCDA ANTIBODY; TCDB ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION; SHUTTLE VECTOR; VERO CELL LINE; VIRUS REPLICATION; WEIGHT REDUCTION; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; CELL LINE; CLOSTRIDIUM INFECTIONS; DISEASE MODEL; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MICROBIOLOGY; MORTALITY; PEPTOCLOSTRIDIUM DIFFICILE; SERODIAGNOSIS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CELL LINE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROTOXINS; GENE EXPRESSION; GENETIC VECTORS; IMMUNOTHERAPY; MICE; NEUTRALIZATION TESTS; SINGLE-DOMAIN ANTIBODIES;

EID: 85015349757     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1093/femspd/ftw078     Document Type: Article

References (46)

1. Adams H, Brummelhuis W, Maassen B et al. Specific immuno capturing of the staphylococcal superantigen toxic-shock syndrome toxin-1 in plasma. Biotechnol Bioeng 2009;104:143- 51.
2. Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:2386-8.
3. Brandt LJ, Aroniadis OC, Mellow M et al. Long-term followup of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:1079-87.
4. Butler MM, Shinabarger DL, Citron DM et al. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Ch 2012;56:4786-92.
5. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol 2007;23:4-9.
6. De BP, Hackett NR, Crystal RG et al. Rapid/sustained antianthrax passive immunity mediated by co-administration of Ad/AAV. Mol Ther 2008;16:203-9.
7. Fang J, Yi S, Simmons A et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 2007;15:1153-9.
8. Fernie DS, Thomson RO, Batty I et al. Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand 1983;53:325-32.
9. Gardiner DF, Rosenberg T, Zaharatos J et al. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009;27:3598-604.
10. Garey KW, Ghantoji SS, Shah DN et al. A randomized, doubleblind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemoth 2011;66:2850-5.
11. Gerding DN, Muto CA, Owens RC. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46 (Suppl 1):S32-42.
12. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53:994- 1002.
13. He X, Sun X, Wang J et al. Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun 2009;77:2294-303.
14. Huang H, Fang H,Weintraub A et al. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infec 2009;15:1170-3.
15. Jager L, Hausl MA, Rauschhuber C et al. A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc 2009;4:547-64.
16. Jiang M, Shi W, Zhang Q et al. Gene therapy using adenovirusmediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006;12:6179-85.
17. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;58:403- 10.
18. Kasuya K, Boyer JL, Tan Y et al. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. Mol Ther 2005;11:237-44.
19. Katchar K, Taylor CP, Tummala S et al. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol H 2007;5:707-13.
20. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-40.
21. Kelly CP, Pothoulakis C, Vavva F et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Ch 1996;40:373-9.
22. Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 1987;55:2984-92.
23. Kotloff KL, Wasserman SS, Losonsky GA et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-95.
24. Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28:965-9.
25. Lessa FC, Mu Y, Bamberg WM et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
26. Liu A, Hoffman PW, LuWet al. NF-kappaB site interacts with Sp factors and up-regulates the NR1 promoter during neuronal differentiation. J Biol Chem 2004;279:17449-58.
27. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection.N Engl J Med 2011;364:422-31.
28. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
29. Lyerly DM, Bostwick EF, Binion SB et al. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991;59:2215-8.
30. Marozsan AJ, Ma D, Nagashima KA et al. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis 2012; 206:706-13.
31. Mukherjee J, Dmitriev I, Debatis M et al. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One 2014;9:e106422.
32. Roberts A, McGlashan J, Al-Abdulla I et al. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun 2012;80: 875-82.
33. Seregin SS, Aldhamen YA, Rastall DP et al. Adenovirusbased vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 2012; 30:1492-501.
34. Sheoran AS, Dmitriev IP, Kashentseva EA et al. Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication. Infect Immun 2015;83: 286-91.
35. Siemann M, Koch-Dorfler M, Rabenhorst G. Clostridium difficileassociated diseases. The clinical courses of 18 fatal cases. Intensive Care Med 2000;26:416-21.
36. Skaricic D, Traube C, De B et al. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology 2008;378:79-85.
37. Sofer-Podesta C, Ang J, Hackett NR et al. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.Infect Immun 2009;77:1561-8.
38. Sun X, Wang H, Zhang Y et al. Mouse relapse model of Clostridium difficile infection. Infect Immun 2011;79: 2856-64.
39. Tremblay JM, Mukherjee J, Leysath CE et al. A single VHH-based toxin neutralizing agent and an effector antibody protects mice against challenge with Shiga toxins 1 and 2. Infect Immun 2013;81:4592-603.
40. Wang H, Sun X, Zhang Y et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012;80:2678-88.
41. Ward SJ, Douce G, Figueiredo D et al. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 1999;67:2145-52.
42. Wesolowski J, Alzogaray V, Reyelt J et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immun 2009;198: 157-74.
43. Yang G, Zhou B,Wang J et al. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol 2008;8:192.
44. Yang Z, Schmidt D, Liu W et al. A novel multivalent, singledomain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 2014;210:964-72.
45. Yu H, Chen K,Wu J et al. Identification of toxemia in patientswith Clostridium difficile infection. PLoS One 2015;10:e0124235.
46. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.